AGEN

SEC source: 0000950170-24-132515 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,093

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 29, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.42 is the closing price of our Common Stock on November 29, 2024, the payroll date for the pay period ending November 29, 2024.

SEC source: 0000950170-24-127933 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,324

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 15, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.72 is the closing price of our Common Stock on November 15, 2024, the payroll date for the pay period ending November 15, 2024.

SEC source: 0000950170-24-127933 · ownership.xml · derivative · entry 4

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2034-11-14

F5 · derivative.exercise_date: Represents a one-time retention award comprised of options to purchase common stock, which were granted to certain key employees, including our executive officers. These options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on November 15, 2025.

SEC source: 0000950170-24-127936 · ownership.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-11-14

F1 · derivative.exercise_date: Represents a one-time retention award comprised of options to purchase common stock, which were granted to certain key employees, including our executive officers. These options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on November 15, 2025.

SEC source: 0000950170-24-127931 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · Chairman Executive Council

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-11-14

F1 · derivative.exercise_date: Represents a one-time retention award comprised of options to purchase common stock, which were granted to certain key employees, including our executive officers. These options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on November 15, 2025.

SEC source: 0000950170-24-127930 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-11-14

F1 · derivative.exercise_date: Represents a one-time retention award comprised of options to purchase common stock, which were granted to certain key employees, including our executive officers. These options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on November 15, 2025.

SEC source: 0000950170-24-120363 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,327

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 1, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.05 is the closing price of our Common Stock on November 1, 2024, the payroll date for the pay period ending November 1, 2024.

SEC source: 0000950170-24-115885 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,300

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 18, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.62 is the closing price of our Common Stock on October 18, 2024, the payroll date for the pay period ending October 18, 2024.

SEC source: 0000950170-24-113183 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,770

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 4, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.87 is the closing price of our Common Stock on October 4, 2024, the payroll date for the pay period ending October 4, 2024.

SEC source: 0000950170-24-112007 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500.664

Underlying: Common Stock · 3,423.478 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-112006 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,671.423

Underlying: Common Stock · 1,252.492 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-112004 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,790.493

Underlying: Common Stock · 3,172.98 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-108934 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,421

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 20, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $5.84 is the closing price of our Common Stock on September 20, 2024, the payroll date for the pay period ending September 20, 2024.

SEC source: 0000950170-24-104710 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,628

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending September 6, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.95 is the closing price of our Common Stock on September 6, 2024, the payroll date for the pay period ending September 6, 2024.

SEC source: 0000950170-24-100797 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,333

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 23, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $5.47 is the closing price of our Common Stock on August 23, 2024, the payroll date for the pay period ending August 23, 2024.

SEC source: 0000950170-24-095518 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,351

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 9, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $5.09 is the closing price of our Common Stock on August 9, 2024, the payroll date for the pay period ending August 9, 2024.

SEC source: 0000950170-24-094126 · ownership.xml · derivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2034-08-07

F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan on August 7, 2024 and will vest in three equal annual installments on each of August 7, 2025, 2026 and 2027 (provided Mr. Harrison maintains a service relationship with the company through each such vesting date).

SEC source: 0000950170-24-087252 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,147

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 26, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $6.56 is the closing price of our Common Stock on July 26, 2024, the payroll date for the pay period ending July 26, 2024.

SEC source: 0000950170-24-083417 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,661

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 12, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $15.60 is the closing price of our Common Stock on July 12, 2024, the payroll date for the pay period ending July 12, 2024.

SEC source: 0000950170-24-079585 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,077.186

Underlying: Common Stock · 2,121.119 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $12.08 per Deferred Stock Unit acquired on July 1, 2024. The price of each Deferred Stock Unit acquired on July 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-079598 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,418.931

Underlying: Common Stock · 776.019 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $12.08 per Deferred Stock Unit acquired on July 1, 2024. The price of each Deferred Stock Unit acquired on July 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-079584 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,617.513

Underlying: Common Stock · 1,827.956 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $12.08 per Deferred Stock Unit acquired on July 1, 2024. The price of each Deferred Stock Unit acquired on July 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-079638 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,615

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 14, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $16.75 is the closing price of our Common Stock on June 28, 2024, the payroll date for the pay period ending June 28, 2024.

SEC source: 0000950170-24-074741 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,642

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 14, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $15.46 is the closing price of our Common Stock on June 14, 2024, the payroll date for the pay period ending June 14, 2024.

SEC source: 0000950170-24-074741 · ownership.xml · derivative · entry 5

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 108,000 shares

Expires 2034-01-11

F6 · derivative.exercise_date: Options were granted on January 17, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 2,160,000 Stock Options with an exercise price of $0.59.

SEC source: 0000950170-24-074741 · ownership.xml · derivative · entry 4

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,651

Underlying: Common Stock · 65,651 shares

Expires 2034-01-17

F5 · derivative.exercise_date: Options were granted on January 17, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 1,313,020 Stock Options with an exercise price of $0.59.

SEC source: 0000950170-24-074837 · ownership.xml · derivative · entry 2

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-01-16

F2 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 200,000 Stock Options with an exercise price of $0.61.

SEC source: 0000950170-24-074837 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,907

Underlying: Common Stock · 37,907 shares

Expires 2034-01-16

F1 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 758,140 Stock Options with an exercise price of $0.61.

SEC source: 0000950170-24-074838 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750

Underlying: Common Stock · 750 shares

Expires 2034-01-26

F1 · derivative.exercise_date: Options were granted on January 26, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 26, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 15,000 Stock Options with an exercise price of $0.66.

SEC source: 0000950170-24-074840 · ownership.xml · derivative · entry 3

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,125

Underlying: Common Stock · 750 shares

Expires 2034-01-26

F3 · derivative.exercise_date: Options were granted on January 26, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 26, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 62,500 Stock Options with an exercise price of $0.66.

SEC source: 0000950170-24-074840 · ownership.xml · derivative · entry 2

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires 2034-01-16

F2 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 125,000 Stock Options with an exercise price of $0.61.

SEC source: 0000950170-24-074840 · ownership.xml · derivative · entry 1

KLASKIN CHRISTINE M · CIK 0001288123 · PFO & PAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,642

Underlying: Common Stock · 10,642 shares

Expires 2034-01-16

F1 · derivative.exercise_date: Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 212,840 Stock Options with an exercise price of $0.61.

SEC source: 0000950170-24-074839 · ownership.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750

Underlying: Common Stock · 750 shares

Expires 2034-01-26

F1 · derivative.exercise_date: Options were granted on January 26, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 26, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 15,000 Stock Options with an exercise price of $0.66.

SEC source: 0000950170-24-067851 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,587

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 31, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $10.86 is the closing price of our Common Stock on May 31, 2024, the payroll date for the pay period ending May 31, 2024.

SEC source: 0000950170-24-062201 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,547

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 17, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $10.86 is the closing price of our Common Stock on May 17, 2024, the payroll date for the pay period ending May 17, 2024.

SEC source: 0000950170-24-054013 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,045

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 3, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $13.07 is the closing price of our Common Stock on May 3, 2024, the payroll date for the pay period ending May 3, 2024.

SEC source: 0000950170-24-046294 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,797

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 19, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $5.31 is the closing price of our Common Stock on April 19, 2024, the payroll date for the pay period ending April 19, 2024.

SEC source: 0000950170-24-042533 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,335,325

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 5, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $0.50 is the closing price of our Common Stock on April 5, 2024, the payroll date for the pay period ending April 5, 2024.

SEC source: 0000950170-24-039491 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,858.238

Underlying: Common Stock · 14,134.924 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $0.66 per Deferred Stock Unit acquired on April 1, 2024. The price of each Deferred Stock Unit acquired on April 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-039351 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,121.341

Underlying: Common Stock · 38,635.459 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $0.66 per Deferred Stock Unit acquired on April 1, 2024. The price of each Deferred Stock Unit acquired on April 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-039357 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,791.152

Underlying: Common Stock · 32,039.161 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $0.66 per Deferred Stock Unit acquired on April 1, 2024. The price of each Deferred Stock Unit acquired on April 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0000950170-24-035663 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,302,628

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 22, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $0.55 is the closing price of our Common Stock on March 22, 2024, the payroll date for the pay period ending March 22, 2024.

SEC source: 0000950170-24-029346 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,275,465

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 8, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $0.67 is the closing price of our Common Stock on March 8, 2024, the payroll date for the pay period ending March 8, 2024.

SEC source: 0000950170-24-020660 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,253,329

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 23, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $0.68 is the closing price of our Common Stock on February 23, 2024, the payroll date for the pay period ending February 23, 2024.

SEC source: 0000950170-24-016075 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 625,969

F1 · price: Open market purchases occurred at a weighted average price of $0.6481 (range of $0.6173 to $0.6525).

F2 · ownership.nature: Shares are held in Dr. Armen's IRA accounts.

SEC source: 0000950170-24-013671 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,231,514

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 9, 2024. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.

F2 · price: $0.75 is the closing price of our Common Stock on February 9, 2024, the payroll date for the pay period ending February 9, 2024.

SEC source: 0000950170-24-046420 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-02-05

F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan on February 5, 2024 and will vest on February 5, 2025. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 100,000 Stock Options with an exercise price of $0.63.

SEC source: 0000950170-24-046417 · ownership.xml · derivative · entry 1

WIINBERG ULF · CIK 0001187314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-02-05

F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan on February 5, 2024 and will vest on February 5, 2025. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 100,000 Stock Options with an exercise price of $0.63.

SEC source: 0000950170-24-046416 · ownership.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-02-05

F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan on February 5, 2024 and will vest on February 5, 2025. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 300,000 Stock Options with an exercise price of $0.63.

SEC source: 0000950170-24-046419 · ownership.xml · derivative · entry 1

Jeynes-Ellis Allison M · CIK 0001758521 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-02-05

F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan on February 5, 2024 and will vest on February 5, 2025. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 100,000 Stock Options with an exercise price of $0.63.